C M DIXON
Overview
Explore the profile of C M DIXON including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Djavan B, Partin A, Hoey M, Roehrborn C, DIXON C, Marberger M
Urology
. 2000 Feb;
55(1):13-6.
PMID: 10654886
No abstract available.
2.
Hoey M, DIXON C, Paul S
J Endourol
. 1998 Dec;
12(5):461-8.
PMID: 9847071
An interstitial saline-electrode has been developed to couple radiofrequency (RF) energy to prostate tissue in order to produce large lesions quickly and controllably. In this study, we attempted to produce...
3.
Barrow A, DIXON C, Saynor D, Perren M, Stowe R, Smith I
Biopharm Drug Dispos
. 1997 Jul;
18(5):443-58.
PMID: 9210982
The pharmacodynamics, pharmacokinetics, metabolism, and excretion of 14C-sumatriptan have been studied in the beagle dog following administration by the intranasal and other routes. The pharmacological response which was monitored, an...
4.
Lepor H, Williford W, Barry M, Brawer M, DIXON C, Gormley G, et al.
N Engl J Med
. 1996 Aug;
335(8):533-9.
PMID: 8684407
Background: Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen...
5.
DIXON C, Colthup P, Kerr B, Boehlert C, Park G, Tarbit M
Drug Metab Dispos
. 1995 Nov;
23(11):1225-30.
PMID: 8591723
Ondansetron is cleared primarily by metabolism in humans, with hydroxylation of the indole moiety in the 7- and 8-positions being the major identified phase I pathways. In vitro studies using...
6.
DIXON C
Urol Clin North Am
. 1995 May;
22(2):441-4.
PMID: 7539189
The TUNA device is a unique system that uses radiofrequency energy to ablate the obstructing prostate adenoma. Although the clinical data are preliminary, they appear to provide improvement in symptom...
7.
DIXON C
Urol Clin North Am
. 1995 May;
22(2):413-22.
PMID: 7539186
In our experience, efficacy favors the TURP and safety the laser. Unlike balloon dilatation of the prostate, there are likely to be technologic advancements that will allow more efficient tissue...
8.
DIXON C, Theune C
J Endourol
. 1995 Apr;
9(2):189-93.
PMID: 7543331
Cost is an extremely complex equation with many variables, but itemized hospital bills are useful in analysis because they reflect costs as defined by an institution. Using this data source,...
9.
DIXON C
World J Urol
. 1995 Jan;
13(2):130-3.
PMID: 7542967
This review highlights some of the caveats assessing the available clinical data base for determining the efficacy, safety, and cost of laser systems used to treat benign prostatic hyperplasia. Many...
10.
DIXON C
World J Urol
. 1995 Jan;
13(2):126-9.
PMID: 7542966
The use of right-angle laser fibers for the treatment of benign prostatic hyperplasia (BPH) has gained widespread acceptance over the past several years. The number of right-angle fibers introduced into...